Other · developed by BeOne Medicines
BGB-B2033 is an agent administered intravenously and studied in hepatocellular carcinoma and liver cancer.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07836530 | Phase 3 | Hepatocellular Carcinoma | Recruiting | ONC |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Hepatocellular CarcinomaLiver Cancer
Updated Oct 25, 2026. Something wrong or missing? Report it on the ONC page.
See ONC's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
ONC catalysts and pipeline →